That glucose intolerance can result from both over-and underactivity of the HIF pathway in beta cells probably reflects the precise interplay between beta cell metabolism and insulin secretion. Such apparently conflicting findings highlight the potential pitfalls of trying to target the HIF pathway therapeutically in beta cells without a greater understanding of its role and regulation. metabolic stress may help to answer some of these questions.
These three studies raise the question of whether HIF-1α activation contributes to beta cell dysfunction in diabetes. In contrast to the new findings [1] [2] [3] , a previous study found that expression of ARNT is actually reduced in islets from humans with type 2 diabetes 9 , and that ARNT inactivation in beta cells impairs insulin secretion, probably as a result of an interplay with other transcription factors regulating beta cell function.
When integrins fail to integrate
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Three studies implicate Kindlin-3, a molecule that mediates signaling through integrins, in a rare disorder characterized by spontaneous bleeding and susceptibility to infection (pages 300-305, 306-312 and 313-318). Integrins, by switching from a resting lowaffinity state to an active high-affinity conformation, can rapidly make blood cells sticky. Tight regulation of this major class of cell adhesion molecules ensures normal blood flow and leukocyte trafficking and mediates rapid adhesion during events such as the formation of a platelet plug after vessel injury.
Several naturally occurring mutations can inactivate the platelet β 3 integrin, leading to Glanzmann's thrombasthenia, characterized by spontaneous bleeding due to defective platelet aggregation, whereas individuals with homozygous mutations in the gene encoding β 2 integrin (CD18) have recurrent infectious complications due to leukocyte adhesion deficiency type 1 (LAD-I) 1 . More recently, individuals showing both Glanzmann's-like and LAD-like symptoms have been described in which the expression of integrins is normal but integrin activity on leukocytes and platelets is defective 2 . This rare but devastating syndrome is termed LAD-I variant or LAD-III.
This syndrome was thought to result from altered signal transduction downstream from G protein-coupled receptors (GPCRs), as their chemokine ligands, major integrin activators, are unable to activate integrins on leukocytes and platelets isolated from people affected with this condition. One potential culprit has been the diacylglycerol-regulated guaninenucleotide exchange factor I (CALDAG-GEF1, official symbol RASGRP2); mice lacking this protein show an LAD-IIIlike phenotype 3 , and a homozygous splice junction mutation in the Caldaggef1 gene has been observed in people with the disease 4 .
In this issue of Nature Medicine, three different groups of researchers point to a more likely culprit [5] [6] [7] . They provide strong evidence that a deficiency in Kindlin-3, a molecule downstream of GPCRs that helps coax integrins into an active conformation, underlies LAD-III 5, 6, 7 .
The Kindlin family of proteins, comprised of three members, is named after Theresa Kindler, who first described a congenital skin blistering condition that combined clinical features of hereditary epidermolysis bullosa and poikiloderma congenitale 8 . The Kindler syndrome is caused by loss-offunction mutations in Kindlin-1 (official symbol FERMT1), which participates in the integrin-dependent anchorage of the actin cytoskeleton within focal adhesions. In mice, deficiency in Kindlin-2 (Kindlin2 −/− ) leads to a failure of the early embryo to implant in the uterus resulting from impaired integrin activation in embryonic stem cells 9 .
Kindlin-3 is expressed in blood cells, and mice lacking the molecule (Kindlin3 −/− ) have defects in platelet aggregation and resistance to arterial thrombosis 7 . These observations led to the question of whether Kindlin-3 is involved in the LAD-III syndrome.
The report by Svensson et al. 5 indeed describes KINDLIN3 mutations in three subjects diagnosed with LAD-III resulting in undetectable expression of the protein.
Whereas two of these subjects also presented a mutation in CALDAGGEF1, no such mutation was found in the third subject.
In the study by Malinin et al. 6 , two siblings showing classical LAD-III symptoms were found to harbor a distinct mutation in the KINDLIN3 gene and had no Kindlin-3 protein expression, whereas expression and function of CALDAG-GEF1 was normal. Importantly, complementation studies in both reports revealed that the enforced expression of Kindlin-3, but not CALDAG-GEF1, restored the adhesive deficiencies in cells lines derived from the subjects.
Interestingly, the two subjects studied by Malinin et al. 6 had osteopetrosis (a condition producing abnormal thickening of the bones) that was suggested to have originated from an enhanced capacity of mesenchymal stem cells to generate bone. However, because Kindlin-3 expression is restricted to the hematopoietic lineage 10 , the cause of the osteopetrosis might lie with osteoclasts, hematopoietic cells mediating α v β 3 integrindependent bone resorption 11 .
Experiments in mice by Moser et al. 7 delved into the mechanism, providing insight into how Kindlin-3 deficiency might lead to disease. As with the LAD-III human cells, leukocytes from mice deficient in Kindlin-3 showed impaired adhesion to and spreading on ligands for β 2 integrins. This translated motifs. Previous studies with Kindlin-2 support a mechanism in which Kindlin-3 binding to the integrin cytoplasmic tail promotes talin binding to the proximal motif, thus leading to integrin activation 9 . Furthermore, Moser et al. 7 found that both Kindlin-2 and Kindlin-3 are required for transducing signals upon integrin engagement ('outside-in' signaling) that allow lamellipodia formation, spreading over a substrate and, in the case of neutrophils, generation of oxygen radicals. Therefore, interactions of Kindlin-3 with the integrin cytoplasmic tail may allow the transmission of signals in both directions.
It is intriguing that Moser et al. 7 have found that Kindlin3 −/− fetal liver-derived hematopoietic stem cells could efficiently reconstitute the hematopoietic system of lethally irradiated mice, a process thought to require β 1 and β 2 integrins. This finding suggests the possibility of differential requirements of leukocyte subtypes for Kindlin-3, the presence of compensatory mechanisms or both. As the in vivo analyses thus far have focused on myeloid cells, studies of other leukocyte subsets such as lymphoid and progenitor cells may shed new light in this regard.
The discovery of this cytoplasmic link provides an important piece in the puzzle of integrin activation and broadens our understanding of the role of integrin modulation in health and disease. mice recapitulated that of mice deficient in adhesion receptors required for leukocyte binding, such as selectins or β 2 integrins, and explains the increase in leukocyte counts and human immunodeficiency reported in the other studies.
The findings in Nature Medicine dovetail with two other recent studies. These have described mutations in the KINDLIN3 gene in all subjects with LAD-III tested (total of 12 individuals) 12, 13 . Whereas the majority of the subjects also harbored the same putative splice site mutation in CALDAGGEF1, two subjects did not.
Despite the wealth of information provided by the new findings, they do not completely exclude a role for CALDAGGEF1. Because the CALDAGGEF1 and KINDLIN3 gene loci are closely positioned on human chromosome 11, Kuijpers et al. 12 have suggested that the CALDAGGEF1 mutation may represent an innocuous intronic single nucleotide polymorphism transmitted through an ancestral haplotype derived from affected Turkish families 12 . Nonetheless, it remains possible that CALDAGGEF1 dysfunction may indeed produce LAD-III-like symptoms, as both proteins operate in the same signaling axis (Fig.  1) , and mice lacking Caldaggef1 have an LAD-III-like phenotype 3 . Owing to their chromosomal proximity (within ~600 megabases on mouse chromosome 19), it is also possible that the knockout mutation in the mouse Caldaggef1 locus might have affected the expression of neighboring genes, although these effects are usually detectable within shorter chromosomal distances 14 . Analyses of Kindlin-3 expression in Caldaggef1 −/− mice will help resolve such issues.
A major challenge will be to elucidate how Kindlin-3 regulates integrin activation. Moser et al. 7 set the stage for future experiments, showing that Kindlin-3 interacts with the cytoplasmic tails of β 1 , β 2 and β 3 integrins at a distal NXXY/F motif distinct from the membrane-proximal NXXY/F motif recognized by talin (Fig. 1) . Importantly, all KINDLIN3 mutations reported by Svensson et al. 5 and Malinin et al. 6 affect the subdomain that mediates the interaction with these into defective arrest of myeloid leukocytes in inflamed venules in vivo and impaired extravasation during inflammation, defects that persisted even after stimulation with chemokines. Figure 1 The right touch. In healthy individuals, integrin activation in leukocytes and platelets is induced by extracellular stimuli through GPCRs and transduced by the CALDAG-GEF1 and Rap1 pathway. These events trigger the binding of a complex containing activated Rap1, Rap1-GTPinteracting adaptor molecule (RIAM), and talin to NXXY/F motifs within the cytoplasmic tail of the β integrin chain. This binding promotes the switch in integrins from low-affinity (inactive, bent form) to high-affinity conformation. This switch mediates leukocyte arrest or platelet aggregation in inflamed or injured vessels (bottom). Kindlin-3 also binds NXXY/F motifs, and, in its absence, leukocyte and platelet integrins remain in low-affinity conformation (LAD-III, right). Three independent studies 5, 7 in this issue of Nature Medicine identify mutations in the gene encoding Kindlin-3 as the molecular basis of known cases of LAD-III. Nonetheless, it remains possible that defects in other molecules involved in the inside-out integrin activation cascade, such as CALDAG-GEFl, could produce a similar syndrome.
